Bristol Myers Gets FDA Expanded Approval of Breyanzi

Bristol Myers Squibb has received expanded FDA approval for its CAR T-cell therapy, Breyanzi, for treating relapsed or refractory marginal zone lymphoma in adults. This makes Breyanzi the only CAR T-cell therapy approved for five cancer types, including this specific lymphoma subtype. The therapy involves genetically engineering a patient's T cells to target cancer cells. Breyanzi generated $966 million in revenue in the first nine months of 2025.